Shaotong Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shaotong Zhang has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Dun Niu
Department of Clinical Biochemistry, Faculty of Pharmacy and Laboratory Medicine, Army Medical University, Chongqing, China
7 shared publications - Jianglang Ran
Department of Clinical Biochemistry, Faculty of Pharmacy and Laboratory Medicine, Army Medical University, Chongqing, China
7 shared publications - Jiqin Lian
Department of Clinical Biochemistry, Army Medical University (Third Military Medical University), Chongqing, China
7 shared publications - Junshi Zhu
Department of Clinical Biochemistry, Faculty of Pharmacy and Laboratory Medicine, Army Medical University, Chongqing, China
7 shared publications - Lu Lu
Department of Clinical Biochemistry, Faculty of Pharmacy and Laboratory Medicine, Army Medical University, Chongqing, China
7 shared publications - Meihua Shan
Department of Clinical Biochemistry, Faculty of Pharmacy and Laboratory Medicine, Army Medical University, Chongqing, China
7 shared publications
Latest Publications
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase–Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficacy
Comparison of the CDUPRT distribution, anti-tumor capacity and toxicity of mCDUPRT versus circCDUPRT after intravenous or intratumoral administration.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase–Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficacy
Comparison of the CDUPRT distribution, anti-tumor capacity and toxicity of mCDUPRT versus circCDUPRT after intravenous or intratumoral administration.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase–Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficacy
The chemical structure of the 5-Flucytosine (5-FC), 5-Fluorouraci (5-FU) and 5-Fluoro-deoxyuridine monophosphate (5-FUMP).
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase–Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficacy
The chemical structure of the 5-Flucytosine (5-FC), 5-Fluorouraci (5-FU) and 5-Fluoro-deoxyuridine monophosphate (5-FUMP).
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase–Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficacy
The sequences of circGFP, circCDUPRT, circIL, and circScram
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase–Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficacy
The sequences of circGFP, circCDUPRT, circIL, and circScram
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase–Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficacy
Comparison of mCDUPRT and circCDUPRT in vitro anti-tumor ability, protein translation ability and prodrug transformation ability under different concentrations and times.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase–Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficacy
Comparison of mCDUPRT and circCDUPRT in vitro anti-tumor ability, protein translation ability and prodrug transformation ability under different concentrations and times.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Data from Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase–Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficacy
Gene-directed enzyme prodrug therapy represents a promising antitumor strategy owing to its low systemic toxicity. However, clinical translation has been hindered by challenges in suicide gene delivery. Artificially engineered circular RNA (circRNA) demonstrates exceptional potential for gene delivery when combined with lipid nanoparticle technology, exhibiting high stability, prolonged protein-coding capacity, and cost-effective production. We developed an in vitro synthesized circRNA encoding the cytosine deaminase–uracil phosphoribosyltransferase (circCDUPRT). Upon intratumoral administration, circCDUPRT achieved sustained intratumoral expression with minimal systemic toxicity. The combination of circCDUPRT and prodrug 5-fluorocytosine showed significant antitumor efficacy in both in vitro and in vivo tumor models. In advanced melanoma models, combining circCDUPRT/5-fluorocytosine with IL-15–expressing circRNA potently enhanced the expansion and activation of CD8+ T and NK cells. Collectively, these findings establish the synthetic circRNA platform as a cost-effective, high-efficiency delivery system for gene-directed enzyme prodrug therapy and immunotherapy applications.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase–Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficacy
Gene-directed enzyme prodrug therapy represents a promising antitumor strategy owing to its low systemic toxicity. However, clinical translation has been hindered by challenges in suicide gene delivery. Artificially engineered circular RNA (circRNA) demonstrates exceptional potential for gene delivery when combined with lipid nanoparticle technology, exhibiting high stability, prolonged protein-coding capacity, and cost-effective production. We developed an in vitro synthesized circRNA encoding the cytosine deaminase–uracil phosphoribosyltransferase (circCDUPRT). Upon intratumoral administration, circCDUPRT achieved sustained intratumoral expression with minimal systemic toxicity. The combination of circCDUPRT and prodrug 5-fluorocytosine showed significant antitumor efficacy in both in vitro and in vivo tumor models. In advanced melanoma models, combining circCDUPRT/5-fluorocytosine with IL-15–expressing circRNA potently enhanced the expansion and activation of CD8+ T and NK cells. Collectively, these findings establish the synthetic circRNA platform as a cost-effective, high-efficiency delivery system for gene-directed enzyme prodrug therapy and immunotherapy applications.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase–Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficacy
Validation of the tumor-targeting capacity and low toxicity of circCDUPRT on a 4T1 tumor-bearing mouse model.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase–Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficacy
Validation of the tumor-targeting capacity and low toxicity of circCDUPRT on a 4T1 tumor-bearing mouse model.
- 30 September 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 25 (2) , 272-282
Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase–Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficacy
Gene-directed enzyme prodrug therapy represents a promising antitumor strategy owing to its low systemic toxicity. However, clinical translation has been hindered by challenges in suicide gene delivery. Artificially engineered circular RNA (circRNA) demonstrates exceptional potential for gene delivery when combined with lipid nanoparticle technology, exhibiting high stability, prolonged protein-coding capacity, and cost-effective production. We developed an in vitro synthesized circRNA encoding the cytosine deaminase–uracil phosphoribosyltransferase (circCDUPRT). Upon intratumoral administration, circCDUPRT achieved sustained intratumoral expression with minimal systemic toxicity. The combination of circCDUPRT and prodrug 5-fluorocytosine showed significant antitumor efficacy in both in vitro and in vivo tumor models. In advanced melanoma models, combining circCDUPRT/5-fluorocytosine with IL-15–expressing circRNA potently enhanced the expansion and activation of CD8+ T and NK cells. Collectively, these findings establish the synthetic circRNA platform as a cost-effective, high-efficiency delivery system for gene-directed enzyme prodrug therapy and immunotherapy applications.
- 30 September 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 25 (2) , 272-282
Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase–Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficacy
Gene-directed enzyme prodrug therapy represents a promising antitumor strategy owing to its low systemic toxicity. However, clinical translation has been hindered by challenges in suicide gene delivery. Artificially engineered circular RNA (circRNA) demonstrates exceptional potential for gene delivery when combined with lipid nanoparticle technology, exhibiting high stability, prolonged protein-coding capacity, and cost-effective production. We developed an in vitro synthesized circRNA encoding the cytosine deaminase–uracil phosphoribosyltransferase (circCDUPRT). Upon intratumoral administration, circCDUPRT achieved sustained intratumoral expression with minimal systemic toxicity. The combination of circCDUPRT and prodrug 5-fluorocytosine showed significant antitumor efficacy in both in vitro and in vivo tumor models. In advanced melanoma models, combining circCDUPRT/5-fluorocytosine with IL-15–expressing circRNA potently enhanced the expansion and activation of CD8+ T and NK cells. Collectively, these findings establish the synthetic circRNA platform as a cost-effective, high-efficiency delivery system for gene-directed enzyme prodrug therapy and immunotherapy applications.